5-MeO-DMT

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026 Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029 NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today reported financial results for the first quarter ended March 31, 2026, and provided a business update across its clinical pipeline. First Quarter 2026 Highlights BPL-003 (TRD): Phase 3 pivotal ReConnection program on track to initiate in Q2 2026. VLS-01 (TRD): Elumina Phase 2 topline results anticipated in Q4 2026. EMP-01 (SAD): Phase 2a data provided validation of EMP-01's potential in Social Anxiety Disorder. Corporate: Inclusion during Q1 2026 in the S&P Biotechnology Select Industry Index and CRSP U.S. indices , which are tracked by a broad range of institutional and passive investor exposure. Cash position: Cash and cash equivalents as of March 31, 2026 expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, said : “Our $209.9 million in cash is expected to provide a runway through our anticipated Phase 3 topline readouts for BPL-003, as we advance toward the late-stage execution phase. Our near-term priority is initiating the Phase 3 ReConnection program for BPL-003 this quarter, while VLS - 01 continues to progress toward anticipated Phase 2 topline results later this year. The positive Phase 2a data for EMP-01 further demonstrated its potential in Social Anxiety Disorder. Collectively, our capital position, pipeline breadth, and multiple near- and mid-term clinical catalysts position us well as we seek to build sustained clinical and shareholder value.” Program Updates BPL-003: mebufotenin benzoate nasal spray for treatment-resistant depression (TRD) On track to initiate Phase 3 program in Q2 2026, following a successful End-of-Phase 2 meeting with the FDA and incorporating regulatory feedback into a registrational Phase 3 design. Phase 3 program consists of two pivotal studies: ReConnection-1 (~350 patients) ReConnection-2 (~230 patients) Primary endpoint: change from baseline in MADRS total score at Week 4. Both studies include a 52-week open-label extension (OLE), allowing individualized 8mg BPL-003 retreatment at 8-week or 12-week intervals with the aim of maintaining remission and evaluating durability and longer-term safety. Phase 2a Part 4 (two-dose induction + SSRIs) cohort initial data on track for Q4 2026. VLS-01: dimethyltryptamine (DMT) buccal film for TRD Elumina Phase 2 study progressing as planned, with topline results anticipated in Q4 2026. EMP-01: Oral R-enantiomer of 3,4-methylenedioxy-methamphetamine (R-MDMA) for social anxiety disorder (SAD) Phase 2a results demonstrated clinically meaningful and consistent improvements across clinician-rated symptoms, patient-reported experience, and real-world behavioral outcomes, providing further evidence of EMP-01’s therapeutic potential in SAD. Business Updates Index inclusions: During the first quarter of 2026, AtaiBeckley was added to the S&P Biotechnology Select Industry Index and multiple CRSP U.S. equity indices , expanding eligibility for index-tracking and passive investment vehicles. In February 2026, AtaiBeckley appointed Michael Faerm as Chief Financial Officer, effective March 9, 2026, bringing more than 25 years of life sciences and capital markets experience, to lead the Company’s financial strategy as BPL-003 advances toward Phase 3. Anticipated Upcoming Milestones Q2 2026: Initiation of BPL-003 Phase 3 ReConnection program Q4 2026: VLS-01 Elumina Phase 2 topline results Q4 2026: BPL-003 Phase 2a Part 4 initial data Early 2029: BPL-003 Phase 3 topline readouts Consolidated Financial Results Cash, cash equivalents, and short-term securities (primarily US treasuries): As of March 31, 2026, the Company had cash, cash equivalents and short-term securities of $209.9 million compared to $220.7 million as of December 31, 2025. The $10.8 million decrease is primarily attributable to $21.1 million used in operations, partially offset by $9.5 million in proceeds from sale of equity holdings. The Company expects its cash, cash equivalents, short-term investments and other liquid assets to fund operations into 2029. Research and development (R&D) expenses: R&D expenses were $17.4 million for the three months ended March 31, 2026 as compared to $11.3 million for the same prior year period. The year-over-year increase of $6.1 million was primarily attributable to higher clinical development and related costs in support of BPL-003, VLS-01 and EMP-01, as well as increased personnel-related expenses as a result of our strategic combination with Beckley Psytech in November 2025. General and administrative (G&A) expenses: G&A expenses for the three months ended March 31, 2026, were $14.4 million as compared to $10.6 million for the same prior year period. The year-over-year increase of $3.8 million was primarily attributable to increased legal, intellectual property, and professional service expenses and increased personnel-related expenses. Net loss: Net loss attributable to stockholders for the three months ended March 31, 2026, was $29.8 million as compared to $26.4 million for the comparable prior year period. About AtaiBeckley Inc. AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable, and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about the AtaiBeckley mission, visit or follow the Company on LinkedIn and on X . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: our business strategy and plans; the potential, success, cost and timing of development of our product candidates, including the progress of preclinical and clinical trials and related milestones; the outcome of past and future interactions with regulatory authorities and our expectations regarding the regulatory pathway for our product candidates; expectations regarding our cash runway and the sufficiency of our cash resources to fund operations through particular milestones; statements regarding our ability to create value for stockholders; and the plans and objectives of management for future operations, research and development and capital expenditures. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) or Quarterly Reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in our other filings with the SEC. Any forward-looking statements made herein speak only as of the date of this press release, and you should not rely on forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, performance or achievements reflected in the forward-looking statements will be achieved or will occur. We disclaim any obligation to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law. Contact Information: Investors: Jason Awe, PhD VP, Investor Relations IR@ataibeckley.com Media: Charlotte Chorley Associate Director, Communications PR@ataibeckley.com – Financial Statements Attached – ATAIBECKLEY, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except share and per share amounts) Three Months Ended March 31, 2026 2025 (unaudited) Revenue $ 954 $ 1,555 Operating expenses: Research and development 17,414 11,328 General and administrative 14,441 10,597 Total operating expenses 31,855 21,925 Loss from operations (30,901 ) (20,370 ) Other income (expense), net 1,119 (5,939 ) Net loss before income taxes (29,782 ) (26,309 ) Provision for income taxes (20 ) (156 ) Net loss (29,802 ) (26,465 ) Net loss attributable to noncontrolling interests (20 ) (34 ) Net loss attributable to AtaiBeckley Inc. stockholders $ (29,782 ) $ (26,431 ) Net loss per share attributable to AtaiBeckley Inc. stockholders — basic and diluted $ (0.08 ) $ (0.15 ) Weighted average shares of common stock outstanding attributable to AtaiBeckley Inc. stockholders — basic and diluted 357,421,528 176,271,176 ATAIBECKLEY, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands) March 31, December 31, 2026 2025 Assets (unaudited) Cash and cash equivalents $ 43,102 $ 85,300 Securities carried at fair value 166,756 135,351 Other current investments held at fair value 20,909 35,389 Prepaid expenses and other current assets 19,299 19,644 Property and equipment, net 2,086 2,166 Operating lease right-of-use assets, net 1,774 1,846 Intangible assets, net 2,763 2,851 Goodwill 331 331 Digital assets 6,765 8,735 Other assets 1,092 1,110 Total assets $ 264,877 $ 292,723 Liabilities and Stockholders' Equity Accounts payable $ 10,785 $ 4,906 Accrued liabilities 9,847 14,168 Current portion of lease liabilities 310 271 Deferred revenue 1,480 1,524 Other current liabilities 2,542 2,610 Contingent consideration liability - related party 104 104 Contingent consideration liabilities 205 205 Noncurrent portion of lease liabilities 1,690 1,801 Pre-funded warrant liabilities 38,397 44,379 Other liabilities 738 754 Total stockholders’ equity attributable to AtaiBeckley Inc. stockholders 198,683 221,874 Noncontrolling interests 96 127 Total liabilities and stockholders' equity $ 264,877 $ 292,723

关注并星标CPHI制药在线 --扫码领取CPHI China2026展会门票-- 数据显示，全球约有3.32亿人患有抑郁症，中国患者规模近1亿，但现有抗抑郁药有效率与治愈率偏低，起效普遍需2—4周。传统单胺类机制的局限日益凸显，行业对快速起效、全新靶点的药物需求迫切。 本文系统梳理2025—2026年全球抗抑郁药物在研进展，覆盖已获批药物、临床阶段突破及前沿靶点方向。 01 抑郁新药获批与监管动态盘点 2025—2026年，全球抗抑郁领域的监管审批呈现“加速推进、品类多元”的特点，FDA作为全球药品监管风向标，在小分子药物、神经调控设备等领域密集出台审批决策，同时跨国药企的并购动作凸显行业对新机制抗抑郁药的高度关注，推动抗抑郁治疗领域的技术迭代与市场扩容。 在小分子药物领域，Caplyta（卢美哌隆）的适应症拓展成为重要突破。2025年下半年，FDA正式批准Caplyta新增重度抑郁症（MDD）辅助治疗适应症，为MDD患者提供了全新的联合治疗选择。此次获批基于两项随机、双盲、安慰剂对照III期临床试验（Study 501和Study 502）的阳性结果，两项研究共纳入1200余名对单一抗抑郁药治疗响应不佳的MDD患者，结果显示，在原有抗抑郁药基础上联合卢美哌隆治疗，6周内患者蒙哥马利-奥斯伯格抑郁量表（MADRS）评分较安慰剂组显著降低（平均降低8.2分vs 4.5分，P<0.001），抑郁症状得到快速改善。更值得关注的是，卢美哌隆的不良反应谱较同类抗精神病药物更优，嗜睡、体重增加、锥体外系反应等发生率显著降低，耐受性良好，解决了传统辅助治疗药物不良反应明显、患者依从性差的痛点，有望成为MDD辅助治疗的一线选择。 针对自杀意念这一抑郁症最危险的并发症，NRX-100的研发进展备受瞩目。2025年底，FDA授予NRX-100（静脉注射氯胺酮）快速通道资格，加速其上市进程，该药计划于2026年6月正式提交新药上市申请（NDA），用于治疗伴有急性自杀意念的抑郁症患者。多项II期对照试验数据显示，NRX-100单次静脉注射后24小时内，即可显著降低患者自杀意念评分（自杀意念量表SSI评分平均降低12.3分，P<0.0001），且疗效持续至72小时，为急性自杀风险患者提供了快速干预的治疗选择。与传统口服抗抑郁药相比，NRX-100的优势在于起效迅速，可快速缓解自杀意念，填补了急性自杀风险抑郁症患者的临床治疗空白，其上市后有望重塑抑郁症急性发作的治疗格局。 除药物外，神经调控设备的获批成为抗抑郁治疗的重要补充。2026年1月，FDA批准Neurolief公司的ProlivRx上市，这是全球首个用于对药物反应不佳的MDD患者的居家神经调控设备，打破了传统神经调控治疗需在医院进行的局限，大幅提升了治疗的可及性。该设备采用外部联合枕骨和三叉神经传入刺激（ecot-as）技术，通过佩戴式耳机向头皮靶向施加温和的无创电脉冲，作用于与抑郁症相关的神经通路，无需全身用药，系统性不良反应风险极低。MOOD临床试验数据显示，使用ProlivRx治疗8周后，HDRS-17抑郁评分较基线平均降低8.62分，显著优于安慰剂组（6.01分，P=0.0196），临床缓解率（HDRS-17评分≤7）达21.3%，显著高于安慰剂组的6.0%（P=0.027）。16周开放标签扩展研究显示缓解率进一步提升至31.7%。该设备为药物治疗无效的MDD患者提供了全新的非药物治疗方案，推动抗抑郁治疗进入“药物+设备”的多元化时代。 在管线推进方面，多款潜力药物进入关键临床阶段。COMP360（裸盖菇素制剂）获准启动创伤后应激障碍（PTSD）IIb/III期临床试验，此前该药在抑郁症领域的临床数据已显示出良好的抗抑郁效果，此次拓展至PTSD领域，有望填补该领域的治疗空白；礼来启动GLP1R/GIPR双激动剂Brenipatide治疗抑郁症的III期研究（RENEW-MDD-1），打破了GLP1类药物仅用于代谢性疾病的局限，探索其在精神领域的治疗潜力，为抑郁症治疗提供了全新的机制方向。 行业并购动作同样凸显抗抑郁新药的研发热度。2025年8月，艾伯维以最高12亿美元收购Gilgamesh Pharmaceuticals的核心在研药物bretisilocin（GM-2505），该药是一款新型短效5-HT2A受体激动剂，正处于治疗中度至重度抑郁症的II期临床开发阶段。此次收购凸显了跨国药企对新机制抗抑郁药物的重视，也反映出行业正从传统5-HT能系统向多靶点、新机制方向转型，推动抗抑郁新药研发进入高质量发展阶段。 02 临床阶段亮点 抗抑郁新药在临床阶段的突破主要集中在难治性抑郁症（TRD）、产后抑郁（PPD）、抑郁症伴日间过度嗜睡（MDD伴EDS）等细分领域，同时国内企业的管线布局逐步发力，形成“全球同步、本土创新”的格局，多款候选药物展现出优异的临床潜力，为不同类型抑郁症患者提供精准治疗方案。 TRD作为抑郁症治疗的难点，其临床需求最为迫切，多款新型给药方式的候选药物在临床阶段取得重大突破。BPL-003（甲氧氟丁胺鼻喷雾剂）是目前TRD领域的潜力品种，该药已获得FDA突破性疗法认定，并计划于2026年Q2启动两项III期临床试验，进一步验证其疗效与安全性。其IIb期核心研究达到主要终点：单次12mg剂量给药后第29天，MADRS评分较基线平均降低11.1分（P=0.0038），8mg剂量组平均降低12.1分（P=0.0025），显著优于0.3mg对照组的5.8分降幅。开放标签扩展研究显示，接受第二次BPL-003给药后，患者响应率达63%，缓解率达48%。该药物采用鼻喷给药方式，生物利用度高，可快速透过血脑屏障，同时不良反应以轻中度为主，主要包括鼻黏膜刺激、短暂头痛等，耐受性良好，有望成为TRD治疗的全新选择。 与BPL-003同为甲氧氟丁胺类药物的GH001（甲氧氟丁胺吸入剂），在TRD领域也展现出优异的临床效果，其IIb期研究结果发表于《JAMA Psychiatry》，进一步证实了该类药物的治疗潜力。该研究纳入81例TRD患者（入组标准为既往对2至5种口服抗抑郁药治疗无应答），GH001组采用单日个性化递增剂量（6+12+18mg）吸入给药，安慰剂组41例。结果显示：GH001组第8天MADRS评分较基线平均降低15.5分，安慰剂组升高0.3分，组间差异-15.5分（P<0.001），效应量达-2.0。第8天缓解率（MADRS评分≤10）GH001组为57.5%（23/40），安慰剂组为0%。进一步分析显示，GH001的疗效与患者既往治疗失败次数无关。安全性方面，GH001的不良事件均为轻中度，无严重不良事件发生，且给药便捷，患者依从性高，与鼻喷剂型形成互补，为TRD患者提供了更多给药方式选择。 产后抑郁（PPD）作为女性特有的抑郁类型，因涉及母婴安全，临床治疗需求尤为迫切，RE104的临床突破为该领域带来新的希望。RE104是一款针对PPD的新型候选药物，其II期临床试验成功达到主要终点，研究纳入80余名产后6个月内的PPD患者。结果显示，单次给药后第7天，77.1%的患者达到临床响应（MADRS评分较基线降低≥50%），71.4%达到临床缓解（MADRS评分≤10），均显著优于安慰剂组（P<0.001），且药物安全性良好，未发现对母婴的不良影响。基于此，FDA授予RE104突破性疗法认定，该药计划于2026年启动III期临床试验，若顺利上市，将填补PPD领域新型药物的空白，为产后女性提供安全、有效的治疗选择。 针对抑郁症伴日间过度嗜睡（MDD伴EDS）这一常见并发症，Solriamfetol的III期临床试验正在稳步推进。Axsome公司启动了CLARITY III期试验，采用撤药设计评估Solriamfetol治疗MDD伴EDS的疗效持久性，该研究纳入300余名MDD伴EDS患者，先接受12周的Solriamfetol治疗，达到临床响应后，随机分为继续给药组和安慰剂撤药组，评估两组患者的复发时间。此前的II期数据显示，Solriamfetol可显著改善MDD患者的日间嗜睡症状，同时对抑郁症状也有一定的改善作用，其独特的作用机制（抑制多巴胺和去甲肾上腺素再摄取）可同时针对抑郁和日间嗜睡两个靶点，有望成为MDD伴EDS患者的精准治疗药物。 国内抗抑郁新药管线同样亮点纷呈，本土企业/研发机构逐步实现从“跟跑”向“并跑”的跨越。绿叶制药的LY03021完成I期临床试验首例患者入组，该药同时靶向去甲肾上腺素转运体（NET）、多巴胺转运体（DAT）和GABA_A受体（GABAAR），是国内首款靶向该组合的三靶点抗抑郁候选药物，其独特的靶点设计有望提升疗效，同时降低不良反应；丽珠医药的NS-041（高选择性KCNQ2/3钾离子通道激动剂）获得CDE批准进入II期临床试验，该药通过调节钾离子通道，改善大脑神经兴奋性，为抑郁症治疗提供了全新的机制方向；致根医药的ZG-001完成7000万元融资，加速其临床推进，该药靶向BDNF-TrkB信号通路，为新型靶点抗抑郁药的代表之一；南方医科大学的LS21031（PDE4抑制剂）启动I期临床试验，探索磷酸二酯酶4通路在抑郁症治疗中的作用，进一步丰富了国内抗抑郁新药的管线布局。 03 从靶点到产业 抗抑郁新药研发已从传统的5-HT能系统，逐步转向多靶点、新机制、精准化方向，靶点多元化、机制创新化、治疗精准化成为行业主流趋势，同时“快速起效+长期安全”的平衡成为研发核心目标，推动抗抑郁治疗领域的技术革新与产业升级。 GABA/谷氨酸能系统成为快速起效抗抑郁药的核心研发方向，多款候选药物通过靶向该系统，实现了“24小时内起效”的突破，打破了传统抗抑郁药的起效瓶颈。绿叶制药的LY03021创新性地同时靶向GABA受体的突触内α1β2γ2亚型与突触外α4β3δ亚型，通过双重调节GABA能系统，快速改善大脑神经递质平衡，其I期临床数据显示，该药给药后24小时内即可观察到抑郁症状的改善，且耐受性良好。另一款候选药物Onfasprodil（MIJ821）则靶向谷氨酸受体NR2B亚型，通过抑制NR2B介导的谷氨酸信号通路，减少神经毒性，实现24小时快速起效。其II期概念验证研究数据显示，0.16mg/kg剂量组24小时MADRS评分较安慰剂降低8.25分（P=0.001），为快速缓解抑郁症状提供了全新的靶点路径。GABA/谷氨酸能系统的研发突破，彻底改变了传统抗抑郁药的起效逻辑，为TRD、急性抑郁发作等患者提供了快速干预的可能。 NK1受体拮抗剂迎来“重获新生”，打破了此前该类药物研发遇冷的困境。传统NK1受体拮抗剂因疗效不佳、不良反应明显，多数研发项目终止，而韩国研究团队通过机器学习虚拟筛选技术，摒弃了传统NK1受体拮抗剂中的TFMP基团，成功开发出具有高选择性、高活性的新型NK1R拮抗剂。该类新型化合物可特异性结合NK1受体，抑制P物质介导的神经炎症反应，同时避免了传统化合物的中枢神经系统不良反应，动物实验与早期临床数据显示，其具有显著的抗抑郁活性，且耐受性良好，为抗抑郁新药研发提供了全新的思路，也推动了NK1受体靶点的重新崛起。 OX2R与5-HT2AR等新机制靶点的探索，进一步丰富了抗抑郁新药的研发格局。Centessa公司的OX2R激动剂通过激活下丘脑的OX2R受体，调节睡眠-觉醒周期，减少抑郁相关的行为绝望，动物实验显示，该类药物可显著改善抑郁模型小鼠的抑郁样行为，且无明显不良反应，目前已进入I期临床试验。国内方面，华西医院的研究团队揭示了5-HT2AR的非经典Gi信号通路，相关研究成果发表于《Nature》，该研究发现，5-HT2AR可通过Gi信号通路调节大脑神经细胞的活性，而非传统的Gs信号通路，这一发现为5-HT2AR靶点的药物研发提供了全新的方向，有望开发出疗效更优、不良反应更少的新型抗抑郁药。 精准精神医学成为抗抑郁新药研发的重要趋势，生物标志物指导下的患者分层与精准治疗逐步落地。HMNC公司的nelivaptan通过伴随诊断技术，检测患者的遗传标志物，实现对抑郁症患者的精准分层，针对不同遗传背景的患者采用个性化给药方案，显著提升了药物的应答率，其II期临床试验数据显示，经过遗传分层后，药物应答率从45%提升至72%。此外，Liafensine的前瞻性研究首次验证了ANK3基因作为TRD治疗的生物标志物，相关成果发表于《JAMA Psychiatry》。ENLIGHTEN研究显示，在ANK3基因阳性的TRD患者中，Liafensine治疗42天后MADRS评分较安慰剂组多降低4.4分（P=0.006），效应量0.42，且治疗仅1周即显著优于安慰剂组。精准精神医学的发展，打破了“一刀切”的治疗模式，推动抗抑郁治疗向“个性化、精准化”转型。 从产业整体趋势来看，抗抑郁新药研发已形成“快速起效+长期安全”的核心导向，多机制联合成为主流方向。传统抗抑郁药多聚焦单一靶点，存在疗效有限、不良反应明显等问题，而新型抗抑郁药多采用多靶点设计或联合用药策略，如同时靶向5-HT与GABA系统、GLP1R与GIPR双激动等，既提升了疗效，又降低了不良反应。同时，靶点多元化格局加速成型，除了传统的5-HT、NE、DA靶点，GABA、谷氨酸、NK1、OX2R等新靶点逐步成为研发热点，推动抗抑郁新药的品类不断丰富。此外，跨国药企与本土企业的研发投入持续增加，国内企业的创新能力逐步提升，管线布局逐步与全球同步，未来将形成“全球竞争、本土创新”的产业格局。 04 结语 抗抑郁新药研发迎来群雄竞逐的黄金时期，从监管审批的加速推进，到临床阶段的多领域突破，再到研发趋势的精准化、多元化，每一项进展都在推动抗抑郁治疗领域的革新。对于本土企业而言，随着管线布局的不断完善与创新能力的提升，有望在全球抗抑郁新药市场中占据一席之地。 注：本文仅作信息交流之目的，文中观点不代表药智网立场，也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 参考来源：FDA官方公告、PubMed收录临床试验数据、企业新闻稿及学术期刊论文（JAMA Psychiatry、Nature等） END 来源：药智网 声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。 投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~